Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients
| Autor: | Orazio Caffo, Michele Lodde, Francesca Maines, Alessandra Perin, Fable Zustovich, Lucia Fratino, Enzo Galligioni, Cosimo Sacco, Sebastiano Buti, Rocco De Vivo, Teodoro Sava, Giovanni Lo Re, Carmen Barile, Angela Gernone, Giovanni L. Pappagallo, Gaetano Facchini, Umberto Basso, Antonello Veccia |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Oncology
Male Cancer Research medicine.medical_specialty medicine.medical_treatment Antineoplastic Agents Docetaxel Castration resistant Drug Administration Schedule law.invention Prostate cancer Quality of life Randomized controlled trial law Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Neoplasm Metastasis Chemotherapy business.industry General Medicine medicine.disease First line treatment Continuous treatment Prostatic Neoplasms Castration-Resistant Treatment Outcome Quality of Life Taxoids business medicine.drug |
| Zdroj: | Future oncology (London, England). 11(6) |
| ISSN: | 1744-8301 |
| Popis: | ABSTRACT Aims: The intermittent administration of chemotherapy is a means of preserving patients’ quality of life (QL). The aim of this study was to verify whether the intermittent administration of docetaxel (DOC) improves the patients’ QL. Patients & methods: All patients received DOC 70 mg/m2 every 3 weeks for eight cycles. The patients were randomized to receive DOC continuously or with a fixed 3-month interval after the first four DOC courses. Results: The study involved 148 patients. There was no difference in QL between the groups receiving intermittent or continuous treatment. Intermittence had no detrimental effects on disease control. Conclusion: Although feasible and not detrimental, our results showed that true intermittent chemotherapy in metastatic castration-resistant prostate cancer patients failed to improve the patients’ QL. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|